Unbiased CRISPR/Cas9 whole genome knockout screens in a human Burkitt lymphoma cell line show that loss of BAX is a major resistance factor for MCL-1-targeting BH3-mimetic drugs. This evidence concerns the gene BAX and Burkitt lymphoma.